keyword
https://read.qxmd.com/read/38490228/systematic-endoscopic-staging-of-mediastinum-to-guide-radiotherapy-planning-in-patients-with-locally-advanced-non-small-cell-lung-cancer-seismic-an-international-multicentre-single-arm-clinical-trial
#21
JOURNAL ARTICLE
Daniel P Steinfort, Gargi Kothari, Neil Wallace, Nicholas Hardcastle, Kanishka Rangamuwa, Edith M T Dieleman, Percy Lee, Peixuan Li, Julie A Simpson, Shaun Yo, Farzad Bashirdazeh, Phan Nguyen, Barton R Jennings, David Fielding, Laurence Crombag, Louis B Irving, Kazuhiro Yasufuku, Jouke T Annema, David E Ost, Shankar Siva
BACKGROUND: Systematic mediastinal lymph node staging by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) improves accuracy of staging in patients with early-stage non-small-cell lung cancer (NSCLC). However, patients with locally advanced NSCLC commonly undergo only selective lymph node sampling. This study aimed to determine the proportion of patients with locally advanced NSCLC in whom systematic endoscopic mediastinal staging identified PET-occult lymph node metastases, and to describe the consequences of PET-occult disease on radiotherapy planning...
March 11, 2024: Lancet Respiratory Medicine
https://read.qxmd.com/read/38488881/stereotactic-body-radiotherapy-for-distant-metastases-to-the-head-and-neck
#22
JOURNAL ARTICLE
Adam Mutsaers, Ahmed Abugharib, Ian Poon, Joshua Loblaw, Andrew Bayley, Liying Zhang, Lee Chin, Madette Galapin, Darby Erler, Arjun Sahgal, Kevin Higgins, Danny Enepekides, Antoine Eskander, Irene Karam
PURPOSE: To report clinical outcomes for patients with metastatic disease to the head and neck (HN) treated with stereotactic body radiation therapy (SBRT). METHODS: A retrospective review of patients treated with SBRT to HN sites from 2012 to 2020 was conducted. Treatment indications included the following: oligometastases, oligoprogression, and control a dominant area of progression (DAP). Kaplan-Meier method was used to estimate local control (LC), regional control (RC), overall survival (OS), and progression-free survival (PFS)...
March 15, 2024: Supportive Care in Cancer
https://read.qxmd.com/read/38484245/reconstruction-of-urethral-sphincter-with-polyacrylamide-hydrogel
#23
JOURNAL ARTICLE
Whitney L Clearwater, Katherine Panushka, Anna Najor, Melissa Laudano, Nicole Fleischmann
IMPORTANCE: Urethral bulking is an alternative to synthetic midurethral sling for the treatment of stress urinary incontinence (SUI) in women. Urethral bulking agents, which are injected in the submucosal tissues of the proximal urethra/bladder neck, have demonstrated less adverse effects with similar satisfaction rates but lower subjective and objective cure rates when compared with midurethral sling. Cystoscopic Reconstruction of External Sphincter Technique (CREST) is a novel technique, which reinforces the natural closure mechanism of the external urinary sphincter (EUS)...
March 1, 2024: Urogynecology (Phila)
https://read.qxmd.com/read/38484193/longitudinal-costs-of-image-guided-intensity-modulated-radiation-therapy-versus-three-dimensional-conformal-radiation-lessons-from-phase-iii-parcer-trial-for-shaping-resource-stratified-guidelines-in-low-and-middle-income-countries
#24
JOURNAL ARTICLE
Varsha Hande, Nilesh Ranjan, Supriya Chopra, Shwetabh Sinha, Prachi Mittal, Ankita Gupta, Amita Maheshwari, Sudeep Gupta
PURPOSE: The PARCER trial provided level I evidence for image-guided intensity-modulated radiation therapy (IG-IMRT) in patients with cervical cancer. Further information regarding long-term financial impact is imperative for adoption into the National Cancer Grid of India cervical cancer resource-stratified guidelines. METHODS: Patient data from the PARCER trial were analyzed to evaluate the cost implications of transitioning to IG-IMRT. Lacking differences in outcomes between the three-dimensional conformal radiation (3D-CRT) and IG-IMRT, differences in treatment costs, adverse event incidence, and toxicity management costs were examined...
March 2024: JCO global oncology
https://read.qxmd.com/read/38477380/hypofractionated-radiation-therapy-combined-with-androgen-deprivation-therapy-for-high-risk-localized-prostate-cancer
#25
JOURNAL ARTICLE
Tae Hoon Lee, Hongryull Pyo, Gyu Sang Yoo, Seong Soo Jeon, Seong Il Seo, Byong Chang Jeong, Hwang Gyun Jeon, Hyun Hwan Sung, Minyong Kang, Wan Song, Jae Hoon Chung, Bong Kyung Bae, Won Park
INTRODUCTION: This study aimed to analyse the treatment outcomes of moderately hypofractionated radiation therapy (RT) combined with androgen deprivation therapy (ADT) and the prognostic implications of prostate-specific antigen (PSA) kinetics in high-risk localized prostate cancer. METHODS: The medical records of 140 patients who underwent definitive RT (70 Gy in 28 fractions) combined with ADT were retrospectively reviewed. ADT consists of a gonadotropin-releasing hormone agonist and an anti-androgen...
March 13, 2024: Journal of Medical Imaging and Radiation Oncology
https://read.qxmd.com/read/38475815/flash-radiotherapy-for-the-treatment-of-symptomatic-bone-metastases-in-the-thorax-fast-02-protocol-for-a-prospective-study-of-a-novel-radiotherapy-approach
#26
JOURNAL ARTICLE
E C Daugherty, Y Zhang, Z Xiao, A E Mascia, M Sertorio, J Woo, C McCann, K J Russell, R A Sharma, D Khuntia, J D Bradley, C B Simone, J C Breneman, J P Perentesis
BACKGROUND: FLASH therapy is a treatment technique in which radiation is delivered at ultra-high dose rates (≥ 40 Gy/s). The first-in-human FAST-01 clinical trial demonstrated the clinical feasibility of proton FLASH in the treatment of extremity bone metastases. The objectives of this investigation are to assess the toxicities of treatment and pain relief in study participants with painful thoracic bone metastases treated with FLASH radiotherapy, as well as workflow metrics in a clinical setting...
March 12, 2024: Radiation Oncology
https://read.qxmd.com/read/38473295/long-term-outcomes-of-ablative-carbon-ion-radiotherapy-for-central-non-small-cell-lung-cancer-a-single-center-retrospective-study
#27
JOURNAL ARTICLE
Shuri Aoki, Hitoshi Ishikawa, Mio Nakajima, Naoyoshi Yamamoto, Shinichiro Mori, Masaru Wakatsuki, Noriyuki Okonogi, Kazutoshi Murata, Yuji Tada, Teruaki Mizobuchi, Ichiro Yoshino, Shigeru Yamada
The aim of this study is to assess the efficacy and safety of ablative carbon ion radiotherapy (CIRT) for early stage central non-small cell lung cancer (NSCLC). We retrospectively reviewed 30 patients who had received CIRT at 68.4 Gy in 12 fractions for central NSCLC in 2006-2019. The median age was 75 years, and the median Karnofsky Performance Scale score was 90%. All patients had concomitant chronic obstructive pulmonary disease, and 20 patients (67%) were considered inoperable. In DVH analysis, the median lung V5 and V20 were 15...
February 25, 2024: Cancers
https://read.qxmd.com/read/38471711/high-response-rate-with-extended-dosing-of-cemiplimab-in-advanced-cutaneous-squamous-cell-carcinoma
#28
JOURNAL ARTICLE
Danny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Sabiha Trabelsi Messai, Friedegund Meier, Thomas K Eigentler, Victoria Casado Echarren, Brian Stein, Marie Beylot-Barry, Sophie Dalac, Brigitte Dréno, Michael R Migden, Axel Hausschild, Chrysalyne D Schmults, Annette M Lim, Suk-Young Yoo, Anne J Paccaly, Apostolos Papachristos, Jenny-Hoa Nguyen, Emmanuel Okoye, Frank Seebach, Jocelyn Booth, Israel Lowy, Matthew G Fury, Alexander Guminski
BACKGROUND: Cemiplimab (Libtayo® ), a human monoclonal immunoglobulin G4 antibody to the programmed cell death-1 receptor, is approved for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC), who are not candidates for curative surgery or curative radiation, using an every-3-weeks (Q3W) dosing interval. Pharmacokinetic modeling indicated that Ctrough of extended intravenous dosing of 600 mg every 4 weeks (Q4W) would be comparable to the approved intravenous dosage of 350 mg Q3W...
March 11, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38471416/durvalumab-in-combination-with-chemoradiotherapy-for-patients-with-unresectable-stage-iii-non-small-cell-lung-cancer-results-from-the-phase-1-clover-study
#29
JOURNAL ARTICLE
Dong-Wan Kim, Byoung Chul Cho, Krishna Pachipala, Sang-We Kim, Chih-Liang Wang, Gee-Chen Chang, Myung-Ju Ahn, Rosa Alvarez, Chao-Hua Chiu, José Trigo, Anna Estival, Sana D Karam, Cathy O'Brien, Hema Gowda, Haiyi Jiang, Julie E Bauman
INTRODUCTION: For patients with unresectable, stage III non-small-cell lung cancer (NSCLC), current standard of care is concurrent chemoradiotherapy (cCRT) followed by consolidation durvalumab. However, earlier initiation of durvalumab simultaneously with cCRT may increase antitumor activity relative to initiation after cCRT. The phase 1 CLOVER study (NCT03509012) evaluated durvalumab combined with cCRT in patients with advanced solid tumors; we report findings from the NSCLC cohort. METHODS: CLOVER comprised a dose-limiting toxicity (DLT) assessment part, followed by an expansion part...
March 7, 2024: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://read.qxmd.com/read/38470404/cost-effectiveness-of-pembrolizumab-plus-lenvatinib-compared-with-chemotherapy-for-treating-previously-treated-advanced-endometrial-cancer-in-sweden
#30
JOURNAL ARTICLE
Lewis Ralph, Kate Young, Navneet Upadhyay, Vimalanand Shrikant Prabhu, Christina Ljungcrantz, Rachid Massaad, Ruifeng Xu, Anna Giertz, Adil Merchant, Robert Orlowski, Linda Duska
OBJECTIVE: Pembrolizumab plus lenvatinib was recently approved for the treatment of advanced or recurrent endometrial carcinoma in women with disease progression on or following prior treatment with a platinum‑containing therapy in any setting, and who are not candidates for curative surgery or radiation (KEYNOTE-775/Study-309; NCT03517449). The objective was to assess the cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy from a Swedish healthcare perspective...
March 12, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38463541/concurrent-nivolumab-and-external-beam-radiation-therapy-for-hepatocellular-carcinoma-with-macrovascular-invasion-a-phase-ii-study
#31
JOURNAL ARTICLE
Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
BACKGROUND AND AIMS: Nivolumab was the first immune checkpoint inhibitor approved for hepatocellular carcinoma (HCC). External beam radiation therapy (EBRT) is locally effective and may enhance the effectiveness of immunotherapy. This study investigated the efficacy and safety of concurrent nivolumab and EBRT in HCC with macrovascular invasion. METHODS: In this phase II multicenter trial, patients with HCC and macrovascular invasion were concurrently treated with intravenous nivolumab (3 mg/kg every 2 weeks) and EBRT, followed by maintenance nivolumab until progression or unacceptable toxicity...
April 2024: JHEP reports: innovation in hepatology
https://read.qxmd.com/read/38459580/protocol-of-a-phase-ii-study-to-evaluate-the-efficacy-and-safety-of-deep-inspiration-breath-hold-daily-online-adaptive-radiotherapy-for-centrally-located-lung-tumours-pudding-study
#32
JOURNAL ARTICLE
Noriko Kishi, Masahiro Yoneyama, Hiroyuki Inoo, Minoru Inoue, Hiraku Iramina, Akiyoshi Nakakura, Tomohiro Ono, Hideaki Hirashima, Takanori Adachi, Norimasa Matsushita, Makoto Sasaki, Takahiro Fujimoto, Mitsuhiro Nakamura, Yukinori Matsuo, Takashi Mizowaki
BACKGROUND: Centrally located lung tumours present a challenge because of their tendency to exhibit symptoms such as airway obstruction, atelectasis, and bleeding. Surgical resection of these tumours often requires sacrificing the lungs, making definitive radiotherapy the preferred alternative to avoid pneumonectomy. However, the proximity of these tumours to mediastinal organs at risk increases the potential for severe adverse events. To mitigate this risk, we propose a dual-method approach: deep inspiration breath-hold (DIBH) radiotherapy combined with adaptive radiotherapy...
March 8, 2024: Radiation Oncology
https://read.qxmd.com/read/38458325/major-complications-and-adverse-events-related-to-use-of-spaceoar-hydrogel-for-prostate-cancer-radiotherapy
#33
JOURNAL ARTICLE
Jack Millot, Camilo Arenas-Gallo, Esther Silver, Mollie Goldman, Shany Picciotto, Angela Y Jia, Nicholas G Zaorsky, Daniel E Spratt, Elisha T Fredman, Jonathan E Shoag
OBJECTIVE: To determine the prevalence and severity of SpaceOARTM -related adverse events using the Manufacturer and User Facility Device Experience (MAUDE) database. METHODS: We analyzed SpaceOAR-related adverse event reports in the Manufacturer and User Facility Device Experience (MAUDE) database from January 2015 to May 2023. For each report, the event type, associated device and patient problems, event description, event timing, and event severity stratified by the Common Terminology Criteria for Adverse Events version 5...
March 6, 2024: Urology
https://read.qxmd.com/read/38453533/percutaneous-interstitial-brachytherapy-ablation-for-targeting-oligometastatic-gynecologic-cancers
#34
JOURNAL ARTICLE
Tiffany S Lai, Alex Francoeur, Erica Manrriquez, Puja Venkat, Albert Chang, Michael Douek, Simin Bahrami, Steven S Raman, Sanaz Memarzadeh
INTRODUCTION: Treatment of recurrent oligometastatic gynecologic malignancy may involve targeted surgery, thermal ablation, or CT-guided high-dose-rate interstitial brachytherapy ablation (CT-HDR-IBTA). The purpose of this study was to describe the safety and efficacy of CT-HDR-IBTA for oligometastatic gynecologic malignancies. METHODS: With institutional review board approval (IRB) approval and compliance with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliance, we searched our database to assemble a single-arm study cohort of all patients with oligometastatic gynecologic cancers who underwent CT-HDR-IBTA from 2012-2022 with follow-up...
March 6, 2024: Brachytherapy
https://read.qxmd.com/read/38451491/stereotactic-radiation-therapy-in-early-non-small-cell-lung-cancer-and-interstitial-lung-disease-a-nonrandomized-clinical-trial
#35
JOURNAL ARTICLE
David A Palma, Houda Bahig, Andrew Hope, Stephen Harrow, Brock J Debenham, Alexander V Louie, Thi Trinh Thuc Toni Vu, Edith Filion, Andrea Bezjak, Marie-Pierre Campeau, Adele Duimering, Meredith E Giuliani, Joanna M Laba, Pencilla Lang, Benjamin H Lok, X Melody Qu, Srinivas Raman, George B Rodrigues, Christopher D Goodman, Stewart Gaede, Julie Morisset, Andrew Warner, Inderdeep Dhaliwal, Christopher J Ryerson
IMPORTANCE: Patients with interstitial lung disease (ILD) and early-stage non-small cell lung cancer (NSCLC) have been reported to be at high risk of toxic effects after stereotactic ablative radiotherapy (SABR), but for many patients, there are limited alternative treatment options. OBJECTIVE: To prospectively assess the benefits and toxic effects of SABR in this patient population. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study was conducted at 6 academic radiation oncology institutions, 5 in Canada and 1 in Scotland, with accrual between March 7, 2019, and January 12, 2022...
March 7, 2024: JAMA Oncology
https://read.qxmd.com/read/38450305/adaptive-ultra-hypofractionated-whole-pelvic-radiotherapy-in-high-risk-and-very-high-risk-prostate-cancer-on-1-5-tesla-mr-linac-estimated-delivered-dose-and-early-toxicity-results
#36
JOURNAL ARTICLE
Linrui Gao, Ran Wei, Shirui Qin, Yuan Tian, Wenlong Xia, Yongwen Song, Shulian Wang, Hui Fang, Yu Tang, Hao Jing, Yueping Liu, Yuan Tang, Shunan Qi, Bo Chen, Yexiong Li, Nianzeng Xing, Ningning Lu
BACKGROUND: Magnetic resonance (MR)-guided ultra-hypofractionated radiotherapy with whole-pelvic irradiation (UHF-WPRT) is a novel approach to radiotherapy for patients with high-risk (HR) and very high-risk (VHR) prostate cancer (PCa). However, the inherent complexity of adaptive UHF-WPRT might inevitably result in longer on-couch time. We aimed to estimate the delivered dose, study the feasibility and safety of adaptive UHF-WPRT on a 1.5-Tesla MR-Linac. METHODS: Ten patients with clinical stage T3a-4N0-1M0-1c PCa, who consecutively received UHF-WPRT, were enrolled prospectively...
March 2024: Chronic Diseases and Translational Medicine
https://read.qxmd.com/read/38448897/stereotactic-ablative-brachytherapy-versus-percutaneous-microwave-ablation-for-early-stage-non-small-cell-lung-cancer-a-multicenter-retrospective-study
#37
MULTICENTER STUDY
Chuanwang Wu, Binglong Cao, Guanghui He, Yuliang Li, Wujie Wang
BACKGROUND: To analyze the efficacy of stereotactic ablative brachytherapy (SABT) and percutaneous microwave ablation (MWA) for the treatment of early-stage non-small cell lung cancer (NSCLC). METHODS: Patients with early-stage (T1-T2aN0M0) NSCLC who underwent CT-guided SABT or MWA between October 2014 and March 2017 at four medical centers were retrospectively analyzed. Survival, treatment response, and procedure-related complications were assessed. RESULTS: A total of 83 patients were included in this study...
March 6, 2024: BMC Cancer
https://read.qxmd.com/read/38448169/-clinical-features-and-prognostic-analysis-of-checkpoint-inhibitor-pneumonitis-in-patients-with-non-small-cell-lung-cancer
#38
JOURNAL ARTICLE
R X Chen, X N Liu, Y Xu, Y J Shi, M Q Wang, C Shao, H Huang, K Xu, M Z Wang, Z J Xu
Objective: To describe the clinical characteristics of patients with non-small cell lung cancer (NSCLC) who developed checkpoint inhibitor pneumonitis (CIP) and to explore potential prognostic factors. Methods: NSCLC patients who were complicated with CIP after immune checkpoint inhibitors (ICIs) therapy in our institute were enrolled in this study from 1 July 2018 to 30 November 2022. Clinical data of NSCLC-CIP patients were collected, including clinical and radiological features and their outcomes. Results: Among the 70 enrolled NSCLC-CIP patients, there were 57 males (81%) and 13 females (19%)...
March 12, 2024: Chinese Journal of Tuberculosis and Respiratory Diseases
https://read.qxmd.com/read/38447771/comparison-of-a-patient-mounted-needle-driving-robotic-system-vs-manual-ct-fluoroscopy-to-perform-percutaneous-ct-guided-lung-biopsies
#39
JOURNAL ARTICLE
Erica Alexander, Elena N Petre, Sylvain Bodard, Brett Marinelli, Debkumar Sarkar, Francois H Cornelis
This preliminary retrospective cohort study aims to compare the efficacy of percutaneous lung biopsy using a patient-mounted needle-driving robotic system or a manual insertion of needles under computed tomography fluoroscopy (CTF) guidance MATERIALS AND METHODS: In this IRB approved study, the cohort consisted of a series of patients who underwent lung biopsies following the intention-to-treat protocol from September 2022 to September 2023, using robot (n=15) or manual insertion under CTF (n=66). Patients and procedures' characteristics were recorded, as well as outcomes RESULTS: While age, body mass index, and skin-to-target distance were not statistically different, target size varied (median: 8 mm [interquartile range: 6...
March 4, 2024: Journal of Vascular and Interventional Radiology: JVIR
https://read.qxmd.com/read/38442285/inflammatory-and-nutritional-biomarkers-in-patients-with-esophageal-squamous-cell-carcinoma-undergoing-neoadjuvant-chemotherapy-and-radiation-therapy
#40
JOURNAL ARTICLE
Chun Hou Huang, Bee Song Chang, Tai-Chu Peng, Yun-Hsin Peng
OBJECTIVES: To investigate the relationship between pretreatment inflammatory and nutritional biomarkers in patients with esophageal squamous cell carcinoma (ESCC) undergoing neoadjuvant chemotherapy and radiation therapy (nCRT). SAMPLE & SETTING: 213 patients with newly diagnosed stage II-III ESCC who received nCRT at an academic hospital in Taiwan. METHODS & VARIABLES: Electronic health record data were used. Records on inflammatory and nutritional biomarkers and clinical outcomes were extracted...
February 19, 2024: Oncology Nursing Forum
keyword
keyword
160170
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.